Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
52.4M
-
Number of holders
-
135
-
Total 13F shares, excl. options
-
49.3M
-
Shares change
-
+16.3M
-
Total reported value, excl. options
-
$502M
-
Value change
-
+$169M
-
Put/Call ratio
-
0.65
-
Number of buys
-
81
-
Number of sells
-
-41
-
Price
-
$10.20
Significant Holders of 2seventy bio, Inc. - Common Stock (TSVT) as of Q1 2023
163 filings reported holding TSVT - 2seventy bio, Inc. - Common Stock as of Q1 2023.
2seventy bio, Inc. - Common Stock (TSVT) has 135 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.3M shares
of 52.4M outstanding shares and own 93.98% of the company stock.
Largest 10 shareholders include Kynam Capital Management, LP (3.74M shares), BlackRock Inc. (3.16M shares), STATE STREET CORP (3.15M shares), VANGUARD GROUP INC (2.9M shares), WELLINGTON MANAGEMENT GROUP LLP (2.77M shares), BAKER BROS. ADVISORS LP (2.5M shares), ORBIMED ADVISORS LLC (2.39M shares), CITADEL ADVISORS LLC (2.37M shares), Casdin Capital, LLC (2.02M shares), and MILLENNIUM MANAGEMENT LLC (1.94M shares).
This table shows the top 135 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.